Capricorn Fund Managers Ltd Takes Position in Phreesia, Inc. $PHR

Capricorn Fund Managers Ltd acquired a new position in shares of Phreesia, Inc. (NYSE:PHR) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 484,500 shares of the company’s stock, valued at approximately $11,395,000. Phreesia accounts for approximately 3.8% of Capricorn Fund Managers Ltd’s investment portfolio, making the stock its 7th largest position. Capricorn Fund Managers Ltd owned approximately 0.81% of Phreesia at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Phreesia by 108.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company’s stock worth $67,606,000 after purchasing an additional 1,377,904 shares in the last quarter. Loomis Sayles & Co. L P acquired a new position in Phreesia during the 2nd quarter worth about $34,162,000. Park West Asset Management LLC boosted its holdings in Phreesia by 111.2% during the 1st quarter. Park West Asset Management LLC now owns 894,501 shares of the company’s stock valued at $22,863,000 after acquiring an additional 470,931 shares during the period. Cambiar Investors LLC acquired a new position in Phreesia in the 2nd quarter valued at about $10,674,000. Finally, Greenhouse Funds LLLP increased its stake in Phreesia by 12.5% during the second quarter. Greenhouse Funds LLLP now owns 3,325,262 shares of the company’s stock worth $94,637,000 after purchasing an additional 368,352 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Price Performance

Phreesia stock opened at $16.99 on Friday. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $20.19 and a 200-day simple moving average of $24.38. The stock has a market cap of $1.02 billion, a P/E ratio of -169.92 and a beta of 0.64. Phreesia, Inc. has a 12-month low of $15.41 and a 12-month high of $32.76.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.11. The firm had revenue of $120.33 million for the quarter, compared to analyst estimates of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.Phreesia’s revenue for the quarter was up 12.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.25) earnings per share. Equities analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Allison C. Hoffman sold 1,241 shares of the business’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $22.36, for a total transaction of $27,748.76. Following the completion of the sale, the general counsel owned 135,737 shares in the company, valued at $3,035,079.32. The trade was a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Evan Roberts sold 1,888 shares of the firm’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $22.36, for a total transaction of $42,215.68. Following the sale, the insider directly owned 724,949 shares in the company, valued at approximately $16,209,859.64. The trade was a 0.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 7,534 shares of company stock worth $165,514 over the last 90 days. 5.50% of the stock is owned by insiders.

Analysts Set New Price Targets

PHR has been the subject of a number of research reports. Piper Sandler lifted their price objective on shares of Phreesia from $33.00 to $34.00 and gave the company an “overweight” rating in a report on Friday, September 5th. Mizuho dropped their price target on shares of Phreesia from $36.00 to $28.00 and set an “outperform” rating for the company in a research note on Wednesday, December 10th. Robert W. Baird cut their price objective on Phreesia from $31.00 to $25.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 10th. Stephens reiterated an “overweight” rating and issued a $32.00 price objective on shares of Phreesia in a research note on Wednesday, September 3rd. Finally, BMO Capital Markets assumed coverage on Phreesia in a research note on Thursday, November 13th. They set an “outperform” rating and a $32.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Phreesia presently has an average rating of “Moderate Buy” and an average price target of $31.00.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.